Immunocore Limited announced the appointment of Professor Sir John Bell, the Regius Professor of Medicine at Oxford University and Chairman of the Office for the Strategic Coordination of Health Research, to its Board of Directors with immediate effect. Professor Bell, distinguished scientists in the fields of genomic and genetic research and immunology, also brings significant experience in healthcare business, having been a founding director at three biotechnology companies; Avidex Limited, Oxagen Limited and PowderJect Pharmaceuticals plc. He currently also serves on the boards of Roche and Genentech and had a previous role on the scientific advisory board at AstraZeneca.